ICU Medical, Inc. (NASDAQ:ICUI) Stock Position Increased by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL lifted its position in ICU Medical, Inc. (NASDAQ:ICUI) by 11.7% during the first quarter, Holdings Channel reports. The institutional investor owned 28,086 shares of the medical instruments supplier’s stock after buying an additional 2,936 shares during the quarter. Gamco Investors INC. ET AL’s holdings in ICU Medical were worth $3,014,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its stake in shares of ICU Medical by 14.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 192,773 shares of the medical instruments supplier’s stock worth $19,227,000 after buying an additional 23,816 shares in the last quarter. WCM Investment Management LLC raised its stake in shares of ICU Medical by 37.5% in the 4th quarter. WCM Investment Management LLC now owns 242,808 shares of the medical instruments supplier’s stock worth $24,223,000 after buying an additional 66,221 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of ICU Medical by 37.8% during the fourth quarter. Principal Financial Group Inc. now owns 107,335 shares of the medical instruments supplier’s stock worth $10,706,000 after purchasing an additional 29,464 shares during the period. Scout Investments Inc. raised its position in shares of ICU Medical by 16.3% during the first quarter. Scout Investments Inc. now owns 51,819 shares of the medical instruments supplier’s stock worth $5,463,000 after purchasing an additional 7,272 shares during the period. Finally, State of Alaska Department of Revenue raised its position in shares of ICU Medical by 417.8% during the fourth quarter. State of Alaska Department of Revenue now owns 12,475 shares of the medical instruments supplier’s stock worth $1,244,000 after purchasing an additional 10,066 shares during the period. Institutional investors own 96.10% of the company’s stock.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, COO Christian B. Voigtlander sold 12,539 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $103.95, for a total value of $1,303,429.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other ICU Medical news, COO Christian B. Voigtlander sold 12,539 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $103.95, for a total value of $1,303,429.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ben Sousa sold 2,000 shares of the business’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $105.55, for a total value of $211,100.00. Following the completion of the sale, the insider now directly owns 1,319 shares of the company’s stock, valued at approximately $139,220.45. The disclosure for this sale can be found here. Insiders have sold 14,839 shares of company stock worth $1,546,014 over the last 90 days. 6.70% of the stock is currently owned by corporate insiders.

ICU Medical Stock Up 2.9 %

NASDAQ ICUI traded up $3.56 on Friday, reaching $128.03. The stock had a trading volume of 197,617 shares, compared to its average volume of 383,935. The business has a 50 day moving average price of $115.90 and a 200 day moving average price of $105.55. The company has a current ratio of 2.61, a quick ratio of 1.09 and a debt-to-equity ratio of 0.76. ICU Medical, Inc. has a 1 year low of $78.28 and a 1 year high of $180.73. The company has a market capitalization of $3.12 billion, a price-to-earnings ratio of -52.26 and a beta of 0.69.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Tuesday, May 7th. The medical instruments supplier reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.06. ICU Medical had a positive return on equity of 5.38% and a negative net margin of 2.63%. The firm had revenue of $566.66 million for the quarter, compared to the consensus estimate of $553.15 million. On average, analysts forecast that ICU Medical, Inc. will post 3.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Raymond James raised ICU Medical from a “market perform” rating to an “outperform” rating and set a $135.00 target price on the stock in a research report on Monday, June 17th. Needham & Company LLC began coverage on ICU Medical in a report on Friday, June 21st. They set a “hold” rating on the stock. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $127.00.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.